Agilent Technologies and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-Based Assays for Early Disease Detection
Advertisement
Agilent Technologies Inc. and Integrated Diagnostics announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes. Officials of both organizations see an opportunity to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on protein and peptide biomarkers of disease.
“Agilent and Integrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving some of mankind’s most vexing health challenges,” said Gustavo Salem, vice president and general manager of the Biological Systems Division at Agilent. “It’s very exciting to be at the forefront of helping technology migrate from the research lab to the clinic, in this case developing next-generation workflows to improve protein-based LC/MS assays.”
The partnership will develop high-throughput automated workflows to include sample preparation and LC MS/MS analysis. Participants expect accelerated biomarker discovery to be fueled by novel sample-prep technology, fast liquid chromatography and ultra-sensitive ion funnel triple quadrupole mass spectrometry.